Tagged: sight diagnostics

OurCrowd Has Stellar 2020, Expects Solid 2021: A Discussion with OurCrowd CEO Jon Medved

OurCrowd is a leading venture marketplace where smaller (accredited) investors can participate in private securities offerings alongside really big investors. A recent example is where JumpCloud, an enterprise cloud service provider, raised $100 million in a Series E Round. OurCrowd’s name was alongside high profile… Read More

Koch Disruptive Technologies Invests in Sight Diagnostics Alongside OurCrowd in $71 Million Series D

Koch Disruptive Technologies has announced an investment in Sight Diagnostics alongside global crowdfunding platform OurCrowd. Sight Diagnostics is a long time portfolio company of OurCrowd. The Series D funding raised a solid $71 million. Total funding now tops $124 million. A valuation of the Medtech… Read More

OurCrowd Portfolio Company Supports Coronavirus Quarantine Needs

Sight Diagnostics, an OurCrowd portfolio company, is helping to lead the response to the Coronavirus pandemic. Sight’s OLO, a compact blood analyzer that can provide rapid, lab-grade CBC [complete blood count] results, has been installed in Sheba Tel Hashomer’s (Israel’s largest hospital that is supported… Read More

Where Theranos Failed, OurCrowd Portfolio Company Sight Diagnostics Succeeds as FDA Clears Finger-Prick Blood Test

We all know the story of Elizabeth Holmes and the demise of Theranos, a company that claimed to have created a device that could provide fast and efficient blood tests. Theranos ended being a company based on hubris, imagination, and vapor. It eventually collapsed being… Read More

OurCrowd Joins $27.8 Million Series C of Sight Diagnostic Creator of Point-of-Care Blood Diagnostics System

OurCrowd has joined in the Series C funding of Medtech firm Sight Diagnostics. The company is creating a lab-grade point-of-care blood diagnostics system “OLO.” This system is designed to provide patients with lab-grade blood testing results in minutes rather than days by combining AI with… Read More

Theranos Like? OurCrowd Portfolio Company Sight Diagnostics Provides Lab Quality Blood Count with Finger Prick Test

Sight Diagnostics, an Israeli Medtech firm, has launched “OLO,” an AI-based blood diagnostics device which is said to offer lab-quality “Complete Blood Count” (CBC) tests from finger prick samples at the point-of-care. Sight Diagnostics is an OurCrowd portfolio company having facilitated two investment rounds in… Read More

Send this to a friend